Cetatea din Alba Iulia a revenit la viață. După o pauză impusă de pandemie, turiștii s-au putut bucura din nou de o lecție de istorie, pusă în scenă de voluntari și de angajați ai muzeului din oraș.
(2)
Press Release for European Medical and Trade Media Only
BIAL announces the end of the licence agreement established in 2009. BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures)
For over a decade, BIAL and Eisai have had an agreement in place for Eisai to market, promote, and distribute eslicarbazepine acetate in Europe. Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe. This move reinforces its continued commitment to and ongoing investment in neurological conditions.
(MENAFN - CDN Newswire) The latest report entitled Global Ulipristal Acetate Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is an in-depth analysis of the global market on the basis of historic growth analysis and the current scenario of the industry. The report consists of a wide range of crucial parameters affecting the growth of the Ulipristal Acetate market. The report is a comprehensive primary and secondary research study which provides market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in near future across the globe. It provides authenticated data based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools to facilitate a deeper understanding of multiple aspects of the global market. The report covers a complete summary of its segments and sub-segments in terms of types and applications.